American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Politics

Novo Nordisk shares surge as Wegovy sales drive profit beat

by admin February 5, 2025
February 5, 2025

Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected fourth-quarter net profit, driven by soaring demand for its obesity treatment, Wegovy.

However, the company warned that sales growth could slow in 2025 as competition intensifies in the weight-loss drug market.

Net profit for the fourth quarter surged 29% year-on-year to 28.23 billion Danish kroner ($3.98 billion), surpassing analyst expectations of 26.09 billion kroner.

For the full year, Novo Nordisk recorded a 21% rise in net profit to 100.99 billion kroner, again exceeding forecasts of 99.14 billion kroner.

Despite these strong results, the company revised its sales growth outlook downward, projecting a 16% to 24% increase for 2025 at constant exchange rates—below the 18% to 26% range forecast for 2024.

Novo Nordisk attributed the cautious outlook to growing competition and pricing pressures in the booming obesity and diabetes drug market.

Wegovy sales surge, but CagriSema setbacks weigh on stock

The company’s obesity drug Wegovy continued its meteoric rise, with sales surging 107% year-on-year to 19.87 billion kroner ($2.76 billion) in the fourth quarter.

However, this figure slightly missed analyst projections of 20.02 billion kroner, reflecting the ongoing supply constraints Novo Nordisk has faced in keeping up with demand.

Wegovy, along with the diabetes drug Ozempic, has transformed Novo Nordisk into Europe’s most valuable company.

However, the firm temporarily lost its top position to French luxury giant LVMH last month following disappointing results from clinical trials for its next-generation weight-loss drug, CagriSema.

CagriSema, a combination of semaglutide—the active ingredient in Wegovy—and amylin analog Cagrilintide, showed an average weight reduction of 22.7% in late-stage trials.

This fell short of the 25% target Novo Nordisk had previously projected, raising concerns about the drug’s potential to become the company’s next blockbuster obesity treatment.

Amycretin fuels investor optimism despite competitive pressure

While the CagriSema trial results dampened enthusiasm, Novo Nordisk has seen renewed investor confidence following positive early-stage results for Amycretin, another experimental obesity drug.

Amycretin, which works by mimicking the amylin hormone produced by the pancreas, has shown promise in helping patients manage weight loss.

Novo Nordisk announced on Wednesday that it would continue further studies on CagriSema in 2025, with plans to file for regulatory approval in early 2026.

The company remains confident in its long-term strategy, despite increasing competition from Eli Lilly’s rival obesity drug, Zepbound.

The broader weight-loss drug market is expected to continue growing rapidly, with analysts predicting it could reach $100 billion in annual sales by the end of the decade.

Novo Nordisk’s ability to maintain its market dominance will depend on its capacity to scale production and bring new, more effective treatments to market.

The post Novo Nordisk shares surge as Wegovy sales drive profit beat appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
next post
SCHD ETF technical analysis: buy, sell or hold in 2025?

Related Posts

Biden’s foreign policy success stems from reversal of...

February 7, 2024

House Judiciary Committee sues FBI agent for defying...

February 7, 2024

Blinken, guitar in hand, sings ‘Rockin’ in the...

May 16, 2024

Biden calls for an end to impeachment inquiry...

February 17, 2024

Biden garners 67K TikTok followers on first day...

February 14, 2024

Trump unable to get $464M appeal bond to...

March 20, 2024

Former Brexit leader Nigel Farage is running in...

June 5, 2024

Biden’s push to protect American tech from China...

February 1, 2024

Netanyahu vows to invade Rafah regardless of potential...

February 26, 2024

3 US service members injured on Gaza humanitarian...

May 25, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025
    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025

    Categories

    • Business (3,032)
    • Investing (2,462)
    • Latest News (1,994)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved